• news.cision.com/
  • OssDsign AB/
  • OssDsign AB (publ) receives initial positive notice regarding reimbursement for OSSDSIGN Cranial PSI in France

OssDsign AB (publ) receives initial positive notice regarding reimbursement for OSSDSIGN Cranial PSI in France

Report this content

OssDsign today announced that the Haute Autorité de Santé (HAS), the French health technology assessment institute, has given an initial positive opinion regarding use of OSSDSIGN Cranial PSI in cranioplasty to be covered by the French national reimbursement system. France is the only remaining European key market where OssDsign to date lacks reimbursement.

Following the notice from the HAS, OssDsign’s application can proceed to the next stage of the application process where a specific reimbursement level for OSSDSIGN Cranial PSI can be determined. As a result of the positive notice from HAS, OssDsign will now intensify its preparations for launching in France during the second half of 2019. France is the only key market in Europe where OssDsign, due to lack of reimbursement, has not yet launched OSSDSIGN Cranial PSI. OssDsign has already established sales organizations and has access to reimbursement systems in the other key European markets.

For further information, please contact:
Anders Lundqvist, CEO, OssDsign AB
Tel: +46 73 206 98 08, email: al@ossdsign.com 

Certified Adviser
The Company’s Certified Adviser is Erik Penser Bank AB. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.

About OssDsign
OssDsign is a Swedish medical technology company that develops and manufactures regenerative implants for improved healing of bone defects. Providing neuro and plastic surgeons with innovative implants, OssDsign improves the outcome for patients with severe cranial and facial defects worldwide. By combining clinical knowledge with proprietary technology, OssDsign manufactures and sells a growing range of patient-specific solutions for treating cranial defects and facial reconstruction. OssDsign's technology is the result of collaboration between clinical researchers at Karolinska University Hospital in Stockholm and material scientists at the Ångström Laboratory at Uppsala University.

This information is information that OssDsign AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 14:00 CET on May 23, 2019 



Documents & Links